OTC: HYEX
HEALTHY EXTRACTS INC.CIK 0001630176 · SIC 2833 · Pharmaceutical Preparations
Micro
Revenue $5M
Assets $33M
as of Oct 11, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
8-K
Filed Sep 18, 2026
· Period ending Sep 13, 2026
Summary not yet generated.
10-Q
Filed Aug 14, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
Partner
Trade HYEX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Jul 24, 2026
· Period ending Jul 17, 2026
Summary not yet generated.
8-K
Filed Jul 13, 2026
· Period ending Jul 7, 2026
Summary not yet generated.
8-K
Filed Jul 6, 2026
· Period ending Jul 1, 2026
Summary not yet generated.
8-K
Filed May 18, 2026
· Period ending May 15, 2026
Summary not yet generated.
10-Q
Filed May 14, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
10-K
Filed Apr 9, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
10-Q
Filed Nov 14, 2025
· Period ending Sep 30, 2025
Summary not yet generated.
8-K
Filed Oct 2, 2025
· Period ending Sep 26, 2025
Summary not yet generated.
10-K
Filed Apr 1, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statement of Operations (Unaudited)
| Description | Three months ending june 30, 2026 | Three months ending june 30, 2025 | Six months ending june 30, 2026 | Six months ending june 30, 2025 |
|---|---|---|---|---|
| REVENUE | ||||
| Revenue | 2,067,212 | 968,656 | 3,677,956 | 1,899,935 |
| Net revenue | 2,067,212 | 968,656 | 3,677,956 | 1,899,935 |
| COST OF REVENUE | ||||
| Cost of goods sold | 614,768 | 375,828 | 1,236,811 | 882,123 |
| Total cost of revenue | 614,768 | 375,828 | 1,236,811 | 882,123 |
| GROSS PROFIT | 1,452,444 | 592,827 | 2,441,145 | 1,017,812 |
| OPERATING EXPENSES | ||||
| General and administrative | 1,501,206 | 698,434 | 2,818,116 | 1,232,267 |
| Total operating expenses | 1,501,206 | 698,434 | 2,818,116 | 1,232,267 |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense, net of interest income | (106,632) | (29,259) | (191,538) | (63,817) |
| Change in fair value on derivative | 21,039 | 201,986 | 304,058 | (53,468) |
| Gain/loss of foreign transactions | 4,966 | - | 4,966 | - |
| Gain/loss of disposal of assets | - | - | (70,000) | - |
| Total other income (expense) | (80,626) | 172,727 | 47,486 | (117,285) |
| Net income/(loss) before income tax provision | (129,389) | 67,120 | (329,486) | (331,739) |
| NET INCOME/(LOSS) | (129,389) | 67,120 | (329,486) | (331,739) |
| Income/(Loss) per share basic and diluted | (0.01) | 0.02 | (0.02) | (0.11) |
| Weighted average number of shares outstanding basic and diluted | 16,344,029 | 3,050,879 | 15,536,102 | 3,050,879 |
Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | 189,958 | 146,935 |
| Accounts receivable | 607,018 | 187,750 |
| Inventory, net | 644,114 | 843,357 |
| Deposit | - | - |
| Offering costs | 149,274 | 149,274 |
| Other current assets | 89,102 | - |
| Total current assets | 1,679,466 | 1,327,317 |
| Fixed assets | 3,884,990 | 4,233,083 |
| Deposit | 37,794 | 99,767 |
| Goodwill | 26,056,515 | 21,123,922 |
| Patents/Trademarks | 526,647 | 526,647 |
| Right of use asset, net non-current | 423,438 | 513,929 |
| Total other assets | 30,929,383 | 26,497,347 |
| TOTAL ASSETS | 32,608,849 | 27,824,664 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| LIABILITIES | ||
| Accounts payable | 340,515 | 108,496 |
| Accrued interest payable | 5,388 | 5,118 |
| Accrued interest payable related party | 116,113 | 76,401 |
| Accrued liabilities | 592,602 | 613,645 |
| Lease liabilities current | 196,815 | 171,930 |
| Notes payable current | 927,824 | - |
| Notes payable related party - current | 6,209,827 | 676,250 |
| Convertible debt, net of discount current | - | 111,330 |
| Total current liabilities | 8,389,085 | 1,763,169 |
| Lease liabilities long-term | 229,110 | 344,265 |
| Notes payable | 1,374,584 | 1,171,670 |
| Notes payable related party - non-current | 125,276 | 156,835 |
| Convertible debt, net of discount non-current | 6,750 | 6,750 |
| Derivative liabilities | 48,353 | 352,411 |
| Total non-current liabilities | 1,784,073 | 2,031,930 |
| Total current and total liabilities | 10,173,158 | 3,795,099 |
| STOCKHOLDERS' EQUITY | ||
| Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding, respectively | - | - |
| Common stock, $0.001 par value, 50,000,000 shares authorized, 14,741,348 shares issued and outstanding as of June 30, 2026, and 16,870,868 shares issued and outstanding as of December 31, 2025 | 368,443 | 368,413 |
| Additional paid-in capital | 46,410,732 | 43,788,013 |
| Treasury stock, at cost, 2,163,686 shares, respectively | (3,892,536) | (5,400) |
| Accumulated deficit | (20,450,948) | (20,121,462) |
| Total stockholders' equity | 22,435,692 | 24,029,564 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 32,608,849 | 27,824,664 |
Consolidated Statement of Cash Flows (Unaudited)
| Description | Six months ending june 30, 2026 | Six months ending june 30, 2025 |
|---|---|---|
| Cash Flows from Operating Activities: | ||
| Net Income/(Loss) | (329,486) | (331,739) |
| Adjustments to reconcile net loss to net cash | ||
| Used in operating activities: | ||
| Depreciation and amortization | 348,093 | 695 |
| Common stock issued for services | 55,824 | 34,169 |
| Gain/loss of disposal of assets | 70,000 | - |
| Discount expensed from note payable and notes payable | 35,734 | |
| Discount expensed from note payable and notes payable- related party | 21,583 | |
| Interest expense | 68,438 | 4,999 |
| Warrants issued for services | 225,389 | 95,152 |
| Change in fair value on derivative liability | (304,058) | 53,468 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (203,463) | 7,024 |
| Deposit | (8,027) | - |
| Inventory | 344,425 | 254,337 |
| Note receivable | - | (100,000) |
| Right of use asset, net current | 221 | - |
| Other current asset | (89,102) | - |
| Accounts payable | 58,263 | 62,641 |
| Accrued liabilities | 118,148 | (24,613) |
| Accrued interest payable | - | 7,072 |
| Accrued interest payable related party | - | 13,240 |
| Lease liability current | - | - |
| Lease liability long-term | - | 793 |
| Net Cash provided by Operating Activities | 411,983 | 77,236 |
| Cash Flows from Investing Activities: | ||
| Fixed assets purchase | - | (19,302) |
| Adli Gummies Inc acquisition | 95,971 | - |
| Cash flows (used in) provided by Investing Activities: | 95,971 | (19,302) |
| Cash Flows from Financing Activities: | ||
| Payments for repayment of convertible debt | (106,000) | (83,437) |
| Proceeds from issuance of noted payable | 316,000 | 160,000 |
| Payments for repayment of notes payable | (245,076) | (8,498) |
| Proceeds from issuance of noted payable related party | 100,000 | - |
| Payments for repayment of noted payable related party | (37,855) | (37,524) |
| Payments for repayment of line of credit | 492,000 | - |
| Interest payment of notes payable | - | - |
| Interest payment of notes payable related party | - | - |
| Net Cash provided by (used in) Financing Activities | (464,931) | 30,540 |
| Increase in cash | 43,023 | 88,474 |
| Cash at beginning of period | 146,935 | 112,020 |
| Cash at end of period | 189,958 | 200,494 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗